Posner Schlossman Syndrome
Conditions
Keywords
Posner Schlossman Syndrome, FK-506, effectiveness, safety
Brief summary
To evaluate the effectiveness and safety of tacrolimus eye drops (FK-506) in the treatment of Posner-Schlossman Syndrome. It is expected to collect 30 patients with PSS who are in the Ophthalmology Department of Peking University Third Hospital. The included PSS patients were divided into experimental group and control group using simple randomization method. Among them, the experimental group was treated with FK-506 twice a day, and the control group was treated with prednisolone acetate ophthalmic suspension 1% 4 times a day. For all PSS patients whose intraocular pressure is higher than 30mmHg, also add brinzolamide eye drops 3 times a day. Best corrected visual acuity, Goldmann intraocular pressure, anterior section photographs, corneal endothelial cells，corneal confocal microscope, Heidelberg retinal nerve analysis, Octopus visual field were examined on baseline and 1 week, 2 weeks, 3 weeks, 4 weeks after the treatment.
Interventions
DRUGFK-506 (Drug)
Twice a day
Four times a day
Sponsors
Peking University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
\- Clinical diagnosis of PSS Must be able to communicate with doctor and understand this study
Exclusion criteria
\- Fuchs syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Silt-lamp examination of the cornea | 1 week after the treatment | KP numbers after the treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Goldmann ophthalmotonometer examination of intra-ocular pressure | 1 week after the treatment | change of intra-ocular pressure |
Countries
China
Contacts
Primary ContactTingting Gao, PHD
Outcome results
None listed